Evidence on Nirsevimab- and Clesrovimab immunization to prevent RSV- associated respiratory tract infections in preterm born children younger than 24 months: a scoping review protocol

Key Points

• To evaluate the effectiveness of nirsevimab and clesrovimab immunization in preventing RSV-related respiratory infections in preterm children under 24 months.
• Conduct a scoping review to gather existing literature
• Focus on preterm children younger than 24 months
• Analyze data regarding nirsevimab and clesrovimab interventions
• Expected to identify gaps in current immunization strategies
• Aim to summarize intervention effects on RSV infections
• Potentially highlight the need for further research in this area